 | |
- close
- close
|
Sydney Morning Herald
Oct 29
Comment
Biotechnology company Biota said it had received written notification from its global marketing partner GlaxoSmithKline (GSK) that its anti-influenza drug Relenza had recorded sales of $331 million for the first quarter generating indicative...
Fusion Investing and Analysis
Oct 28
Comment
Relenza sales were £182 million reflecting continued orders from Governments for pandemic stockpiling. That's around $23M in royalties for Biota.
£45M in US
£38 in Europe
£99 RoW
Royalties owing to Biota Holdings (BTA) from GSK's...
Fusion Investing and Analysis
Oct 28
Comment
GSK's Q3 09 webcast is on 28 October 2009 at 13:30 GMT, 00.30 Melbourne Time.
They'll announce quarterly Relenza sales, provide an update on production and possibly on Rotacap/Rotahaler.
Royalty estimates for BIOTA HOLDINGS LIMITED (BTA) range...
Fusion Investing and Analysis
Oct 25
Comment
In the case of Wrist vs Saw, the saw won. I'm off to the doctors in a few minutes to get some stitches. My accident, which is a nicer way of saying my stupidity, actually happened on Saturday. I was hoping to heal thy self, but alas upon seeing my...
Red Orbit
Oct 7
Comment
Ancient soil biota decreased in size by up to 46 percent during period 55 million years agoAncient soil-inhabiting creatures decreased in body size by nearly half in response to a period of boosted carbon dioxide levels and higher temperatures,...
Fusion Investing and Analysis
Oct 6
Comment
My kids started back in school yesterday and I've 'celebrated' by diving into phase two of our taxes. This is the one time of the year I seriously think about simplifying our finances. Our discretionary trust and personal taxes are so frigging...
Fusion Investing and Analysis
Sep 15
Comment
Daybagger definition and a quick comment or two on Biota, Prana and MMC Contrarian.
The Australian
Aug 19
Comment
DRUG developer Biota has delivered a full-year net profit of $38.2 million thanks to increased demand from governments that stocked up on its flu treatment Relenza to fight the pandemic.
The Australian
Aug 13
Comment
ANTI-FLU drug developer Biota Holdings plans to return$20 million to shareholders, after finding it has excess capital as it looks forward to greater earnings from its flagship product, Relenza.
Fusion Investing and Analysis
Aug 13
Comment
Biota Holdings Limited (ASX: BTA) intends to make a return of $20 million to shareholders, estimated to equate to approximately 11 cents per share. The good news is Biota management are attactively managing their capital and are clearly confident...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| ||||||
|
|
